J. Saez de la Fuente, A. Such Díaz, C. Sánchez Gil, C. Esteban Alba, I. Escobar Rodríguez
{"title":"增强蛋白酶抑制剂单药治疗HIV+患者有效性的meta分析","authors":"J. Saez de la Fuente, A. Such Díaz, C. Sánchez Gil, C. Esteban Alba, I. Escobar Rodríguez","doi":"10.1016/S2173-5085(10)70018-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The objective of this study is to analyse the available evidence regarding the effectiveness of the strategy of induction maintenance with boosted protease inhibitors with ritonavir in adult HIV patients as compared to conventional treatment.</p></div><div><h3>Methods</h3><p>We performed a meta-analysis of randomised controlled trials in HIV patients to compare the efficacy of a monotherapy strategy of boosted protease inhibitors as compared with conventional antiretroviral therapy. The literature search was conducted in PubMed, EMBASE (September 1999-September 2009) and in conference abstracts of the last 5 years. The Odds Ratio of treatment failure and their 95% confidence intervals were calculated. To combine the results of individual studies selected, a fixed effects model based on the Mantel-Haenszel method or random effects was used, depending on whether or not the results were heterogeneous.</p></div><div><h3>Results</h3><p>Initially a total of 1510 publications were found, of which just 8 studies met the criteria for inclusion in the meta-analysis. The combined Odds Ratio of the 8 studies is 1.39 (95% CI 1.02–1.90) for the treatment group with conventional antiretroviral treatment, but with a confidence interval close to the limits of statistical non-significance.</p></div><div><h3>Conclusion</h3><p>The results of the combined effectiveness analysis in the meta-analysis found no significant differences between the conventional strategy and monotherapy. This strategy is considered recommended (level A evidence) in patients with no history of previous failure of protease inhibitor, with undetectable plasma viral load and signs or symptoms of nucleoside/nucleotide toxicity.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"34 5","pages":"Pages 237-244"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S2173-5085(10)70018-6","citationCount":"2","resultStr":"{\"title\":\"Meta-analysis of the effectiveness of the strategy of monotherapy with boosted protease inhibitors in HIV+ patients\",\"authors\":\"J. Saez de la Fuente, A. Such Díaz, C. Sánchez Gil, C. Esteban Alba, I. Escobar Rodríguez\",\"doi\":\"10.1016/S2173-5085(10)70018-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>The objective of this study is to analyse the available evidence regarding the effectiveness of the strategy of induction maintenance with boosted protease inhibitors with ritonavir in adult HIV patients as compared to conventional treatment.</p></div><div><h3>Methods</h3><p>We performed a meta-analysis of randomised controlled trials in HIV patients to compare the efficacy of a monotherapy strategy of boosted protease inhibitors as compared with conventional antiretroviral therapy. The literature search was conducted in PubMed, EMBASE (September 1999-September 2009) and in conference abstracts of the last 5 years. The Odds Ratio of treatment failure and their 95% confidence intervals were calculated. To combine the results of individual studies selected, a fixed effects model based on the Mantel-Haenszel method or random effects was used, depending on whether or not the results were heterogeneous.</p></div><div><h3>Results</h3><p>Initially a total of 1510 publications were found, of which just 8 studies met the criteria for inclusion in the meta-analysis. The combined Odds Ratio of the 8 studies is 1.39 (95% CI 1.02–1.90) for the treatment group with conventional antiretroviral treatment, but with a confidence interval close to the limits of statistical non-significance.</p></div><div><h3>Conclusion</h3><p>The results of the combined effectiveness analysis in the meta-analysis found no significant differences between the conventional strategy and monotherapy. This strategy is considered recommended (level A evidence) in patients with no history of previous failure of protease inhibitor, with undetectable plasma viral load and signs or symptoms of nucleoside/nucleotide toxicity.</p></div>\",\"PeriodicalId\":100521,\"journal\":{\"name\":\"Farmacia Hospitalaria (English Edition)\",\"volume\":\"34 5\",\"pages\":\"Pages 237-244\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S2173-5085(10)70018-6\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmacia Hospitalaria (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173508510700186\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508510700186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
本研究的目的是分析与传统治疗相比,利托那韦增强蛋白酶抑制剂诱导维持策略在成年HIV患者中的有效性的现有证据。方法:我们对HIV患者的随机对照试验进行了荟萃分析,以比较增强蛋白酶抑制剂单一治疗策略与常规抗逆转录病毒治疗的疗效。检索PubMed、EMBASE(1999年9月- 2009年9月)和近5年的会议摘要。计算治疗失败的优势比及其95%置信区间。为了结合所选择的单个研究的结果,根据结果是否异质性,使用基于Mantel-Haenszel方法的固定效应模型或随机效应。结果最初共发现1510篇出版物,其中只有8篇研究符合纳入meta分析的标准。接受常规抗逆转录病毒治疗的治疗组,8项研究的综合优势比为1.39 (95% CI 1.02-1.90),但置信区间接近无统计学意义的极限。结论meta分析的综合疗效分析结果显示,常规策略与单药治疗之间无显著差异。对于没有蛋白酶抑制剂失效史、血浆病毒载量检测不到、核苷/核苷酸毒性体征或症状的患者,推荐使用该策略(A级证据)。
Meta-analysis of the effectiveness of the strategy of monotherapy with boosted protease inhibitors in HIV+ patients
Introduction
The objective of this study is to analyse the available evidence regarding the effectiveness of the strategy of induction maintenance with boosted protease inhibitors with ritonavir in adult HIV patients as compared to conventional treatment.
Methods
We performed a meta-analysis of randomised controlled trials in HIV patients to compare the efficacy of a monotherapy strategy of boosted protease inhibitors as compared with conventional antiretroviral therapy. The literature search was conducted in PubMed, EMBASE (September 1999-September 2009) and in conference abstracts of the last 5 years. The Odds Ratio of treatment failure and their 95% confidence intervals were calculated. To combine the results of individual studies selected, a fixed effects model based on the Mantel-Haenszel method or random effects was used, depending on whether or not the results were heterogeneous.
Results
Initially a total of 1510 publications were found, of which just 8 studies met the criteria for inclusion in the meta-analysis. The combined Odds Ratio of the 8 studies is 1.39 (95% CI 1.02–1.90) for the treatment group with conventional antiretroviral treatment, but with a confidence interval close to the limits of statistical non-significance.
Conclusion
The results of the combined effectiveness analysis in the meta-analysis found no significant differences between the conventional strategy and monotherapy. This strategy is considered recommended (level A evidence) in patients with no history of previous failure of protease inhibitor, with undetectable plasma viral load and signs or symptoms of nucleoside/nucleotide toxicity.